Protective Role of Humanin on Bortezomib-Induced Bone Growth Impairment in Anticancer Treatment

Bortezomib is a proteasome inhibitor currently studied in clinical trials of childhood cancers. So far, no side effects on bone growth have been reported in treated children. However, bortezomib was recently found to induce apoptosis in growth plate chondrocytes and impair linear bone growth in treated mice. We hypothesize that [Gly(14)]-humanin (HNG), a 24-amino acid synthetic antiapoptotic peptide, can prevent bortezomib-induced bone growth impairment. Mice with human neuroblastoma or medulloblastoma tumor xenografts (913 animals/group) received one 2-week cycle (2 injections/week) of bortezomib (0.8mg/kg or 1.0mg/kg), or HNG (1 g/mouse), or the combination of HNG/bortezomib, or vehicle. Cultures of human growth plate cartilage, chondrogenic- and cancer cell lines, and immunohistochemistry for detection of proapoptotic proteins were also used. Statistical significance was evaluated by two-sided MannWhitney U test or by parametric or nonparametric analysis of variance. Bortezomib efficiently blocked the proteasome and induced pronounced impairment of linear bone growth from day 0 to day 13 (0.09mm/day, 95% confidence interval [CI] 0.07 to 0.11mm/day; vs 0.19mm/day, 95% CI 0.15 to 0.23mm/day in vehicle; P < .001), an effect significantly prevented by the addition of HNG (0.15mm growth/day, 95% CI 0.14 to 0.16mm/day; P < .001 vs bortezomib only; P 0.03 vs vehicle). Bortezomib was highly toxic when added to cultures of human growth plate cartilage, with markedly increased apoptosis compared with control (P < .001). However, when combining with HNG, bortezomib-induced apoptosis was entirely prevented, as was Bax and PARP activation. Bortezomib delayed tumor growth, and HNG did not interfere with the anticancer effect when studied in human tumor xenografts or cell lines. HNG prevents bortezomib-induced bone growth impairment without interfering with bortezomibs desired anticancer effects.